Filing Analysis
Akebia Therapeutics, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2026. The filing serves as a formal announcement of quarterly earnings and recent business highlights.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2026.
- Filing date: August 5, 2026.
- The company issued a press release (Exhibit 99.1) containing financial results and business highlights.
Akebia Therapeutics announced that its VOICE clinical trial met predefined stopping criteria for non-inferiority and superiority of the primary composite endpoint. Based on interim analysis results, USRC Kidney Research has decided to stop the trial early due to these positive outcomes.
📋 Key Facts
- VOICE trial met predefined stopping criteria as of June 1, 2026 data cutoff.
- Trial established non-inferiority and superiority of Vafseo (vadadustat) vs. standard-of-care ESA for the primary composite endpoint.
- Primary composite endpoint win odds: 1.16 (95% CI 1.06, 1.28, p=0.0016).
- Statistically significant decrease in hospitalizations: 1.11 vs 1.23 per patient year (IRR 0.90; 95% CI 0.824, 0.988).
- No statistically significant difference in mortality rates (8.77% vs 8.78%).
- Trial design: Randomized, open-label, active controlled trial with 2,116 patients.
Akebia Therapeutics entered into an Asset Purchase Agreement with Q32 Bio Inc. to acquire ADX-097, a clinical-stage complement inhibitor for rare kidney diseases. The deal includes an upfront payment of $10 million (split over two installments) and significant contingent milestone/royalty payments.
🚩 Red Flags
- Significant contingent liabilities via milestone payments and royalties totaling over $580 million in potential outflows.
- Standard cautionary language regarding the uncertainty of cash runway and ability to achieve operating plans.
📋 Key Facts
- Acquisition of all assets and liabilities related to ADX-097 from Q32 Bio Inc. and Q32 Bio Operations Inc.
- $7.0 million upfront payment made on November 28, 2025.
- $3.0 million additional upfront payment due on the six-month anniversary of closing.
- Potential development/regulatory milestones totaling up to $94.5 million.
- Potential commercial milestone payments totaling up to $487.5 million based on net sales.
- Royalty obligations ranging from low single digits to mid-teen percentages.
- Company expects current cash resources to fund operations for at least 2 years.
Akebia Therapeutics entered into Amendment #1 to its existing License Agreement with Medice Arzneimittel Putter GmbH & Co. KG on November 12, 2025. The amendment expands the partnership by including a supply agreement for vadadustat drug substance and granting manufacturing rights for Vafseo tablets.
📋 Key Facts
- Amendment #1 to License Agreement signed with Medice Arzneimittel Putter GmbH & Co. KG on November 12, 2025.
- Akebia will supply vadadustat drug substance ('Drug Substance') to Medice under a concurrent supply agreement.
- Medice is granted rights to manufacture Vafseo tablets using the supplied Drug Substance.
- Intellectual Property Clause: Any know-how or patent rights arising from Medice's manufacture of Vafseo tablets will be owned by Akebia Therapeutics.
Akebia Therapeutics, Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2025. The filing serves as a formal mechanism to furnish recent business highlights and quarterly earnings via a press release.
📋 Key Facts
- Report date: November 10, 2025
- Reporting period: Third quarter ended September 30, 2025
- The filing includes Exhibit 99.1 containing the official press release of financial results.
- CEO John P. Butler signed the report.
Akebia Therapeutics announced that it will not initiate the VALOR clinical trial for vadadustat due to a lack of alignment with the FDA regarding trial design. Consequently, the company is abandoning its plans to pursue a broad label for Vafseo in non-dialysis dependent chronic kidney disease (CKD) patients.
🚩 Red Flags
- Significant setback in product pipeline/label expansion strategy
- Failure to reach regulatory alignment on a key clinical program (VALOR)
- Loss of potential market segment (non-dialysis CKD patients) for Vafseo
📋 Key Facts
- Company met with the FDA regarding the VALOR clinical trial design for vadadustat.
- No alignment was reached with the FDA on the path forward for the study.
- The Company will not initiate the VALOR clinical trial.
- The Company will not pursue a broad label for Vafseo for CKD non-dialysis dependent patients.
Akebia Therapeutics, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2025. The filing serves as a formal announcement of recent business highlights and quarterly performance.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Second Quarter ended June 30, 2025
- The company issued a press release (Exhibit 99.1) containing financial results and business highlights.
- Signed by John P. Butler, President and CEO.
Akebia Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 10, 2025. The meeting included the election of two directors and approval of several shareholder proposals.
📋 Key Facts
- Annual Meeting held on June 10, 2025.
- Stockholders approved an amendment to the 2023 Stock Incentive Plan, increasing available shares by 18,900,000.
- John P. Butler and Myles Wolf, M.D., elected as Class II directors until the 2028 annual meeting.
- Say-on-pay (executive compensation) was approved on an advisory basis.
- Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
Akebia Therapeutics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025, and provided recent business highlights via a press release.
📋 Key Facts
- Reporting period: First quarter ended March 31, 2025.
- Filing date: May 8, 2025.
- The filing includes the announcement of financial results and recent business highlights via Exhibit 99.1.
Akebia Therapeutics announced a significant underwritten public offering of 25,000,000 shares of common stock at $2.00 per share to raise approximately $46.5 million in net proceeds. The offering is intended to support the company's path toward profitability.
🚩 Red Flags
- Significant dilution for existing shareholders due to the large volume of new shares issued.
- Company explicitly states it 'may never achieve profitability' in its Regulation FD disclosure.
📋 Key Facts
- Offering size: 25,000,000 shares of common stock.
- Public offering price: $2.00 per share; Underwriter purchase price: $1.88 per share.
- Underwriters include Leerink Partners LLC and Piper Sandler & Co.
- Estimated net proceeds: ~$46.5 million (up to ~$53.6 million if the 3,750,000 share over-allotment option is exercised).
- Expected closing date: March 21, 2025.
- The offering is being conducted via a shelf registration statement on Form S-3 (File No. 333-281903).
Akebia Therapeutics, Inc. has filed an 8-K to furnish its quarterly press release regarding financial results for the fourth quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 13, 2025
- Reporting period: Fourth quarter and fiscal year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results and business updates.
- Information under Item 2.02 is furnished rather than filed for purposes of Section 18 liability.
Akebia Therapeutics has extended its existing loan facility with Kreos Capital VII (UK) Limited, resulting in a $9.3 million cash drawdown and the issuance of over 1.15 million warrants to the lender.
🚩 Red Flags
- Liquidity dependency: The company is drawing down debt tranches to fund operations, indicating a need for immediate cash.
- Equity dilution: Issuance of 1.15M warrants at $1.30 per share represents significant potential future dilution for existing shareholders.
- Short-term extension: The Tranche C expiry was only extended by approximately one month (from Dec 31 to Feb 3), suggesting a very tight liquidity runway.
📋 Key Facts
- Entered into Second Amendment to the Agreement for the Provision of a Loan Facility on February 3, 2025.
- Extended the expiry date of 'Tranche C' from December 31, 2024, to February 3, 2025.
- Drew down $9.3 million in net proceeds (after fees and expenses) on February 3, 2025.
- Issued a warrant for 1,153,846 shares of common stock at an exercise price of $1.30 per share.
- The warrant is exercisable for eight years.
Akebia Therapeutics announced its intention to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The company also provided a liquidity update stating that existing cash resources are expected to fund operations for at least two years.
🚩 Red Flags
- Standard cautionary language regarding the uncertainty of achieving operating plans or securing additional funding.
📋 Key Facts
- CEO John P. Butler will present at the J.P. Morgan Healthcare Conference on Jan 16, 2025.
- Company expects current cash and cash from operations to fund its operating plan (including Vafseo® launch) for at least two years.
- The filing includes a presentation as Exhibit 99.1.
Akebia Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024, and recent business highlights.
📋 Key Facts
- Report date: November 7, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and business highlights.
Akebia Therapeutics, Inc. has entered into a multi-year commercial supply agreement with a leading dialysis organization to provide access to its product Vafseo® (vadadustat) for patients undergoing dialysis.
📋 Key Facts
- Agreement Date: October 22, 2024
- Product involved: Vafseo® (vadadustat)
- Counterparty: A leading dialysis organization
- Term: Multi-year commercial supply agreement
Akebia Therapeutics has entered into an amendment to its existing Supply Agreement with STA Pharmaceutical Hong Kong Limited. The amendment extends the manufacturing term for vadadustat and modifies pricing structures.
📋 Key Facts
- Amendment #1 to the Supply Agreement was executed on October 15, 2024.
- The term of the agreement is extended until January 1, 2032.
- The amendment includes changes to the volume-based pricing structure for vadadustat drug product.
- STA Pharmaceutical Hong Kong Limited remains the manufacturer for the Product.
Akebia Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024, and provided recent business highlights via a press release.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes results of operations and financial condition (Item 2.02).
- A press release was issued as Exhibit 99.1.
Akebia Therapeutics terminated its exclusive license agreement with CSL Vifor for the product Vafseo, transitioning to a royalty-based settlement model. The company also amended its $55 million senior secured loan facility with Kreos Capital (BlackRock) in connection with this termination.
🚩 Red Flags
- Significant cash outflow obligations: The company faces mandatory 'True-Up' payments totaling up to $40M by 2028, creating significant liquidity pressure.
- Complex royalty structures and potential for high long-term cost of goods/sales due to multiple layers of royalties (WCF and Settlement).
- The termination is linked to loan covenant amendments, suggesting the restructuring impacts existing debt terms.
📋 Key Facts
- Termination of Second Amended and Restated License Agreement with CSL Vifor effective July 10, 2024.
- Akebia must repay a $40 million Working Capital Fund via tiered royalty payments (8% to 14%) starting July 1, 2025, through May 31, 2028.
- Mandatory 'True-Up' payments of $10M, $20M, and $40M are required on May 31 of 2026, 2027, and 2028 if cumulative royalties are insufficient.
- Additional Settlement Royalty Payments apply to Vafseo sales in the U.S. territory until patent/regulatory exclusivity expires.
- Akebia has a 'Royalty Buy-Down Option' starting July 1, 2027, to reduce settlement royalty rates.
- Amended existing $55 million senior secured term loan facility with Kreos Capital VII (UK) Limited.
Akebia Therapeutics, Inc. announced the appointment of Erik Ostrowski as Senior Vice President, CFO, CBO, Treasurer, and principal financial officer, effective June 24, 2024.
📋 Key Facts
- Erik Ostrowski appointed as SVP, CFO, Chief Business Officer, Treasurer, and principal financial officer.
- Effective date of appointment is June 24, 2024.
- Base salary set at $540,000 per year with an annual bonus target of up to 45% of base salary.
- Equity compensation includes 500,000 stock options (4-year vesting) and 350,000 RSUs (3-year vesting).
- Mr. Ostrowski previously served as President/Interim CEO/CFO at AVROBIO, Inc.
Akebia Therapeutics, Inc. held its Annual Meeting of Stockholders on June 6, 2024. The meeting resulted in the election of three Class I directors and the ratification of Ernst & Young LLP as independent auditors, though a proposal to increase shares under the 2023 Stock Incentive Plan was rejected.
🚩 Red Flags
- Shareholders rejected the proposal to increase the share pool in the 2023 Stock Incentive Plan, which may indicate investor dissatisfaction with dilution or current compensation structures.
📋 Key Facts
- Annual Meeting held on June 6, 2024.
- Three Class I directors (Ronald E. Frieson, Steven C. Gilman, Ph.D., and Cynthia Smith) were elected to serve until the 2027 annual meeting.
- The proposal to increase common stock available under the 2023 Stock Incentive Plan by 9,800,000 shares was NOT approved (52,820,792 votes against vs. 45,155,875 for).
- Say-on-pay advisory vote regarding executive compensation was approved.
- Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2024 was approved.
Akebia Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2024, and provided recent business highlights via a press release.
📋 Key Facts
- Report date: May 9, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes results of operations and financial condition (Item 2.02)
- Press release issued as Exhibit 99.1
Akebia Therapeutics has drawn down a portion of its existing senior secured term loan facility with Kreos Capital VII (UK) Limited. The company received $7.5 million in net proceeds on April 19, 2024, following the drawdown of Tranche B.
🚩 Red Flags
- Continued reliance on debt financing to fund operations/liquidity.
- The drawdown of specific tranches suggests active management of cash runway.
📋 Key Facts
- The Company drew down the 'Tranche B Loan' portion of its existing loan facility on April 17, 2024.
- Net proceeds received were $7.5 million on April 19, 2024 (after deducting fees and expenses).
- The total Term Loan Facility has an aggregate principal amount of up to $55.0 million.
- Initial tranche of $37.0 million was funded on January 29, 2024.
- A remaining $10.0 million in borrowing capacity (Tranche C) remains available under the agreement.
Akebia Therapeutics entered into Amendment #2 to its Supply Agreement with STA Pharmaceutical Hong Kong Limited. The amendment extends the manufacturing agreement for vadadustat drug substance by five years and modifies the volume-based pricing structure.
📋 Key Facts
- Amendment #2 to the Supply Agreement was executed on April 15, 2024.
- The term of the Supply Agreement is extended by five years, now expiring on April 2, 2029.
- The amendment includes changes to the volume-based pricing structure for vadadustat drug substance.
- STA Pharmaceutical Hong Kong Limited remains the manufacturer for commercial purposes.
Akebia Therapeutics announced that the FDA has approved its New Drug Application (NDA) for Vafseo® (vadadustat) tablets. The drug is indicated for treating anemia in adults with chronic kidney disease who have been receiving dialysis for at least three months.
📋 Key Facts
- FDA approval received on March 27, 2024.
- Product: Vafseo® (vadadustat) tablets.
- Indication: Treatment of anemia due to chronic kidney disease in adults receiving dialysis for at least three months.
Akebia Therapeutics announced the departure of its Senior Vice President, Chief Financial Officer (CFO), and Treasurer, Ellen Snow, effective March 22, 2024. CEO John Butler will serve as the interim principal financial officer following her transition.
🚩 Red Flags
- Sudden departure of a CFO in a micro-cap/biotech environment can sometimes signal internal friction or financial reporting concerns, though no restatement was noted here.
- Interim leadership (CEO acting as PFO) can create operational strain and delays in financial oversight.
📋 Key Facts
- Ellen Snow to transition from CFO role on March 22, 2024.
- Departure is by mutual agreement.
- Severance includes 12 months of base salary continuation and up to 12 months of COBRA premium reimbursement.
- Unvested equity awards will continue to vest during the severance period.
- John Butler (CEO) will assume the role of interim principal financial officer.
Akebia Therapeutics, Inc. filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended December 31, 2023, alongside business updates.
📋 Key Facts
- Report date: March 14, 2024
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) containing financial results and business updates.
Akebia Therapeutics announced amendments to the separation agreements for its Chief Operating Officer, Michel Dahan, and Senior Vice President/Chief Legal Officer, Nicole R. Hadas. Both executives have agreed to extend their effective separation dates into mid-to-late 2024.
🚩 Red Flags
- Successive delays in executive departures can sometimes indicate transition friction or ongoing litigation/disputes, though not explicitly stated here.
📋 Key Facts
- Michel Dahan (COO) separation date extended from March 22, 2024, to June 28, 2024.
- Nicole R. Hadas (SVP, CLO) separation date extended from March 29, 2024, to June 14, 2024.
- The extensions were agreed upon on February 8, 2024.
- Separation dates could potentially extend as far as September 22, 2024, depending on specified events.
Akebia Therapeutics entered into a $55 million senior secured term loan facility with Kreos Capital VII (managed by BlackRock) to replace an existing Pharmakon loan. The financing includes significant warrant coverage and is heavily contingent upon FDA approval of the company's drug, vadadustat.
🚩 Red Flags
- High interest rate environment (SOFR + 6.75%) with a significant default penalty (+3.0% spread).
- Significant dilution risk via warrants totaling over 4.2 million shares.
- Heavy dependency on FDA approval of vadadustat to avoid accelerated repayment and extend maturity.
- Strict financial covenant requiring $15M minimum cash balance.
📋 Key Facts
- Entered into a $55.0 million senior secured term loan facility with Kreos Capital VII (UK) Limited on January 29, 2024.
- Initial tranche of $37.0 million funded immediately; net proceeds approximately $34.5 million after fees.
- Additional tranches: $8.0M (Tranche B) and $10.0M (Tranche C), both contingent on FDA approval of vadadustat.
- Interest rate is SOFR + 6.75% (floor 4.25%, cap 15.00%).
- Warrant issuance: 3,076,923 shares at $1.30 exercise price; additional 1,153,846 shares contingent on Tranche C drawdown.
- Maturity date is March 31, 2025, but extends to January 29, 2028, if vadadustat receives FDA approval by June 30, 2024.
- Financial covenant requires maintaining $15 million in cash or $150 million in trailing twelve-month revenue.
Akebia Therapeutics, Inc. announced the appointment of Richard C. Malabre as Chief Accounting Officer and principal accounting officer, effective January 8, 2024.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Richard C. Malabre appointed as Chief Accounting Officer (CAO) and principal accounting officer on Jan 8, 2024.
- Malabre will report to Ellen Snow, SVP, CFO, Treasurer, and principal financial officer.
- Compensation includes a $380,000 annual base salary and an annual cash bonus target of up to 35% of base salary.
- Equity grants include 336,000 stock options (4-year vesting) and 223,950 Restricted Stock Units (RSUs) (3-year vesting).
- Malabre previously served as CFO at Ultivue, Inc. and VP/Corporate Controller at Oxford Immunotec USA, Inc.
Akebia Therapeutics announced its intention to present preliminary unaudited net product revenue for Auryxia® at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024.
📋 Key Facts
- CEO John P. Butler will present at the J.P. Morgan Healthcare Conference on Jan 11, 2024, at 11:15 a.m. PST.
- Presentation includes preliminary unaudited net product revenue for Auryxia® (cumulative and fiscal year ended Dec 31, 2023).
- Management will also hold various investor and analyst meetings starting January 8, 2024.